PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-1141.09%
Negative net income growth while VET stands at 94.59%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
-7.68%
Both reduce yoy D&A, with VET at -32.38%. Martin Whitman would suspect a lull in expansions or intangible additions for both.
110.71%
Well above VET's 80.15% if it’s a large positive yoy. Michael Burry would see a bigger future tax burden vs. competitor’s approach.
171.05%
SBC growth while VET is negative at -29.49%. John Neff would see competitor possibly controlling share issuance more tightly.
-243.37%
Both reduce yoy usage, with VET at -178.65%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
-25.62%
AR is negative yoy while VET is 0.00%. Joel Greenblatt would see a short-term cash advantage if revenue remains unaffected vs. competitor's approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-243.37%
Both reduce yoy usage, with VET at -178.65%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
54.72%
Some yoy increase while VET is negative at -94.44%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
-79.33%
Both yoy CFO lines are negative, with VET at -102.57%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
68.10%
CapEx growth well above VET's 81.86%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
40.00%
Acquisition spending well above VET's 74.14%. Michael Burry would suspect heavier integration risk or short-term free cash flow drain vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-293.85%
Both yoy lines negative, with VET at -232.11%. Martin Whitman suspects a cyclical or strategic rationale for cutting extra invests in the niche.
21.07%
Investing outflow well above VET's 34.77%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
56.76%
Debt repayment above 1.5x VET's 13.87%, indicating stronger deleveraging. David Dodd would verify if expansions are not neglected.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.